Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
Stockholders approved the conversion of the preferred stock issued in the June 2026 acquisition of Azora Therapeutics